Tech Company Financing Transactions
Nivagen Pharmaceuticals Funding Round
Nivagen Pharmaceuticals, operating out of Sacramento, received $16 million from Telegraph Hill Partners and private investors.
Transaction Overview
Company Name
Announced On
5/20/2020
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Undisclosed
Investors
Telegraph Hill Partners (Lead Investor) (Robert Hart)
Proceeds Purpose
Nivagen intends to use the proceeds for internal development and acquisition of additional generic and branded drugs to broaden its product portfolio.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3100 Fite Circle 208
Sacramento, CA 95827
USA
Sacramento, CA 95827
USA
Phone
Undisclosed
Website
Email Address
Overview
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Shukla
Chief Financial Officer
Robert Miller
Chief Scientific Officer
Dasaradhi Lakkaraju
VP - R & D
Anand Shukla
VP - Sales
Andrea Felix
VP - Sales
Thomas Henry
Browse more venture capital transactions:
Prev: 5/20/2020: Confluera venture capital transaction
Next: 5/20/2020: Amplyx Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs